Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Kojiro HataKimitaka SuetsuguNobuaki EgashiraYoko MakiharaShinji ItohTomoharu YoshizumiMasatake TanakaMotoyuki KohjimaHiroyuki WatanabeSatohiro MasudaIchiro IeiriPublished in: Cancer chemotherapy and pharmacology (2020)
Maintaining Ctrough median above 42.68 ng/mL was crucial for achieving the ORR in patients with HCC.
Keyphrases